2021 reportable list - connecticut

State of Connecticut Department of Public Health Connecticut Tumor Registry

2021 Reportable List

ALL LICENSED HEALTHCARE PROVIDERS IN CONNECTICUT ARE REQUIRED TO REPORT CANCER CASES DIAGNOSED OR TREATED AT THEIR FACILITY TO THE CONNECTICUT TUMOR REGISTRY (CTR). THISINCLUDES ALL CONDITIONS LISTED IN THE INTERNATIONAL DISEASES FOR ONCOLOGY, THIRD EDITION (ICD-0-3) WITH A BEHAVIOR CODE OF /2 OR /3, AND IN APPROVED UPDATES, EXCEPT AS NOTED BELOW.

GENERAL CONSIDERATIONS:

All malignancies diagnosed from 1935 forward are reportable. Benign brain and central nervous system tumors diagnosed from 1962 forward are reportable. Non-resident cases diagnosed 1979 forward are reportable. Cases diagnosed clinically are reportable. Cases in patients being treated for cancer are reportable. Cases diagnosed prior to birth (in utero) are reportable only when the pregnancy results in a live birth.

When a reportable diagnosis is confirmed prior to birth and disease is not evident at birth due to regression, accession the case based on the pre-birth diagnosis.

Urinary tract malignancies diagnosed by positive urine cytology from 2013 forward are reportable. • Code the primary site to C689 in the absence of any other information. • Exception: When a subsequent biopsy of a urinary site is negative, do not report. • Do not implement new/additional casefinding methods to capture these cases. • Do not report cytology cases with ambiguous terminology.

Refer to the Hematopoietic and Lymphoid Neoplasm Coding Manual and Database for additional information on hematopoietic and lymphoid neoplasms.

Effective for cases diagnosed January 1, 2021 forward, ICD-O-3.2 is the preferred reference for morphology codes. The Connecticut Tumor Registry recommends using the 2021 ICD-O-3 Histology and Behavior Code Update tables jointly with ICD-O-3.2, Hematopoietic and Lymphoid Neoplasm Database, and Solid Tumor rules.

For 2021, the High-Level Strategic Group (HLSG) approved new terms which have been added to ICD-O-3.2 for use in the United States and Canada beginning with cases diagnosed on or after January 1, 2021. These new terms include both reportable and non-reportable neoplasms. For 2021, major changes apply to reportability. 16 previously non-reportable neoplasms become

reportable. 9 reportable pre-2021 neoplasms become non-reportable. 10 histology terms have been moved to other ICD-O codes. 13 histologies have a change in reportable terminology. 12 new terms/ICD-O codes.

The NAACCR Combined 2021 ICD-O-3.2 Update Table is included as an appendix to the Reportable List

2021 ICD-O-3 Update is to be used jointly with ICD-O-3.2, Solid Tumor Rules, and Hematopoietic and Lymphoid Neoplasm Database (https://www.naaccr.org/icdo3/)

Please see Appendix

https://www.naaccr.org/icdo3/




NEWLY REPORTABLE CONDITIONS AND TERMS:

Early or evolving melanoma, in situ and invasive: As of 1/1/2021, early or evolving melanoma in situ, or any other early or evolving melanoma, is reportable.

All GIST tumors are reportable as of 01/01/2021. The behavior code is /3 in ICD-O-3.2. Nearly all thymomas are reportable as of 01/01/2021. The behavior code is /3 in ICD-O-3.2. The exceptions

are Microscopic thymoma or thymoma, benign (8580/0) Micronodular thymoma with lymphoid stroma (8580/1) Ectopic hamartomatous thymoma (8587/0)

Report benign and borderline primary intracranial and central nervous system (CNS) tumors with a behavior code of /0 or /1 in ICD-O-3 (effective with cases diagnosed 01/01/2004 to 12/31/2020) or ICD-O-3.2 (effective with cases diagnosed 01/01/2021 and later). See the table below for the specific sites.

Report Pilocytic/Juvenile astrocytomas; code the histology and behavior as 9421/3 when the primary site is C71._Exception: The behavior is non-malignant when the primary site is optic nerve (C723).

OTHER REPORTABLE CONDITIONS:

Anal intraepithelial neoplasia III (AIN III) of the anus or anal canal (C210-C211), laryngeal intraepithelial neoplasia III (LIN III) (C320-C329), high grade biliary intraepithelial neoplasia (BiIN III) of the gallbladder (C239), Lobular (intraepithelial) neoplasia grade III (LIN III) of the breast (C500-C509), pancreatic intraepithelial neoplasia (PanIN III) (C250-C259), squamous intraepithelial neoplasia III (SIN III) excluding cervix, vaginal intraepithelial neoplasia III (VAIN III) (C529), and vulvar intraepithelial neoplasia III (VIN III) (C510-C519), penile intraepithelial neoplasia (PeIN III) (C600-C609) are reportable.

Carcinoid, NOS of the appendix is reportable. As of 1/1/15, the ICD-O-3 behavior code changed from /1 to /3.

Report Pilocytic/Juvenile astrocytomas; code the histology and behavior as 9421/3. Non-invasive mucinous cystic neoplasm (MCN) of the pancreas with high grade dysplasia is reportable. For

neoplasms of the pancreas, the term MCN with high grade dysplasia replaces the term mucinous cystadenocarcinoma, non-invasive.

Bronchial adenoma, carcinoid type (8240/3) and cylindroid type (8200/3) are reportable. Argentaffin tumors (8241/3) are reportable. Lobular carcinoma in situ (LCIS) of the breast is reportable. Osteomyelofibrosis (9961/3) Pancreatic endocrine tumor, malignant (8150/3) Mixed pancreatic, endocrine and exocrine tumor, malignant (8154/3) Mixed adenoneuroendocrine carcinoma (8244/3) Gastrointestinal stromal tumors (GIST) and thymomas are reportable when there is evidence of multiple

foci, lymph node involvement, or metastasis. Mature teratoma of the testis in adults is malignant and reportable; it is not reportable in prepubescent

children.



EXCEPTIONS-MALIGNANT HISTOLOGIES THAT ARE NOT REPORTABLE:

Skin primaries with any of the following histologies (6/1/1984): Malignant neoplasm (8000-8005) Epithelial carcinoma (8010-8046) Papillary or squamous cell carcinomas (8050-8084) Basal cell carcinoma

Skin primaries of the genital sites: vagina, clitoris, vulva, prepuce, penis, and scrotum (C52.9, C51.0-C51.9, C60.0, C60.9 and C63.2) are reportable.

AIN III arising in perianal skin Carcinoma in situ of the cervix (C530-C539; behavior /2); cervical intraepithelial neoplasia (CIN III or SIN III)

is not reportable. (1/1/1996) Prostatic intraepithelial neoplasia (PIN III) is not reportable. (1/1/2001)

REPORTABLE BENIGN NEOPLASMS:

All benign and borderline primary brain and central nervous system tumors (C70.0-C72.9) Benign and borderline tumors of the pituitary, craniopharyngeal duct, and pineal gland (C75.1-C75.3) Report pilocytic/juvenile astrocytoma; code to 9421/3 Neoplasm and tumor are reportable terms for brain and CNS

Behavior code of /0 or /1 in ICD-O-3 A brain or CNS neoplasm identified only by imaging is reportable

REQUIRED SITES FOR BENIGN AND BORDERLINE PRIMARY BRAIN AND CNS TUMORS

General Term Specific Sites ICD-0-3 Topography Code

Meninges Cerebral meninges Spinal meninges Meninges, NOS

C700 C701 C709

Brain Cerebrum C710 Frontal lobe C711 Temporal lobe C712 Parietal lobe C713 Occipital lobe C714 Ventricle, NOS C715 Cerebellum, NOS C716 Brain stem C717 Overlapping lesion of brain C718 Brain, NOS C719

Spinal cord, cranial nerves, and Spinal Cord C720 other parts of the central nervous Cauda equine C721 system Olfactory nerve C722

Optic nerve C723 Acoustic nerve C724



Cranial nerve, NOS Overlapping lesion of the brain And central nervous system

C725 C728

Nervous system, NOS C729 Pituitary, craniopharyngeal ductand pineal gland

Pituitary gland Craniopharyngeal duct Pineal gland

C751 C752 C753

AMBIGUOUS TERMINOLOGY:

Ambiguous terminology may originate in any source document, such as a pathology report, radiology report, or clinical report. The terms listed below are reportable when they are used with a term such as cancer, carcinoma, sarcoma, etc.

Use the reportable ambiguous terms when screening diagnoses on pathology reports, scans, ultrasounds, and other diagnostic testing other than tumor markers

The following ambiguous terms that are considered reportable:

Apparent(ly) Appears Comparable with Compatible with Consistent with Favor(s) Malignant appearing Most Likely Presumed Probable Suspect(ed) Suspicious (for) Typical (of)

The following ambiguous terms are not considered reportable:

Approaching Cannot (be) ruled out Equivocal Possible Potential(ly) Questionable Rule out Suggests Very close to Worrisome

Do not substitute synonyms such as “supposed” for “presumed” or “equal” for comparable. Do not substitute “likely” for “most likely”. If any of the ambiguous terms precede either the word “tumor” or the word “neoplasm” case is

REPORTABLE. “Mass” and “lesion” are not reportable terms for intracranial and CNS because they are not listed in ICD-O-

3.2 with behavior codes of /0 or /1 Do not use ambiguous terminology when reporting cytology

Appendix: NAACCR ICD-O-3.2 Update Table

ICD-O Update Effective January 1, 2021i

Combined 2021 ICD-O-3.2 update (alpha)

Status abbreviations used in the update table

Status Definition BC Behavior code change (change in reportability) CC Per ICD-O-3.2, several ICD-O codes have been deleted and the histologies moved to other codes. NC/T New ICD-O code and term PT Preferred term RT Related term Syn Synonym

Histology terms are per WHO. Preferred terms are indicated in BOLD font. Applicable C codes will be noted next to the term in BOLD font. Coding instructions, if applicable, are noted in the “Comments” column.

1


Status ICD-O-3.2 Morphology Code

Term(s) Reportable Y/N

Comments

RT 8140/3 Acinar adenocarcinoma of prostate (C61.9) Y Syn 8744/3 Acral lentiginous melanoma, malignant (C44. _) Y PT 8744/3 Acral melanoma (C44. _) Y BC 8158/3 ACTH-producing tumor Y Reportable for cases

diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

PT 9840/3 Acute erythroid leukemia Y CC 9687/3 Acute leukemia, Burkitt type [obs] Y Cases diagnosed prior to

1/1/2021 use code 9826/3 Cases diagnosed 1/1/2021 forward use code 9687/3

CC 9687/3 Acute lymphoblastic leukemia, mature B-cell type Y Cases diagnosed prior to 1/1/2021 use code 9826/3 Cases diagnosed 1/1/2021 forward use code 9687/3

NC/T 9912/3 Acute myeloid leukemia with BCR-ABL1 Y Reportable for cases diagnosed 1/1/2021 forward

NC/T 9878/3 Acute myeloid leukemia with biallelic mutations of CEBPA Y Reportable for cases diagnosed 1/1/2021 forward

NC/T 9877/3 Acute myeloid leukemia with mutated NPM1 Y Reportable for cases diagnosed 1/1/2021 forward

NC/T 9879/3 Acute myeloid leukemia with mutated RUNX1 Y Reportable for cases diagnosed 1/1/2021 forward

Syn 9840/3 Acute myeloid leukemia, M6 type Y Syn 8140/3 Adenocarcinoma, usual type Y PT 8390/3 Adnexal adenocarcinoma (C44. _) Y Syn 8700/3 Adrenal medullary paraganglioma (C74.1) Y Reportable for cases

diagnosed 1/1/2021 forward.

2


Not reportable prior to 1/1/2021

Syn/BC 8408/3 Aggressive digital papillary adenoma (C44. _) see comments* See comments

The term “Aggressive digital papillary adenoma” has changed behavior from /1 to /3. Cases diagnosed prior to 1/1/2021 with this term are not reportable. Cases with this term diagnosed 1/1/2021 and after are reportable

Syn 9310/3 Ameloblastoma, malignant Y PT 9310/3 Ameloblastoma, metastasizing Y NC/T 9715/3 Anaplastic large cell lymphoma, ALK negative Y Reportable for cases

diagnosed 1/1/2021 forward RT 8020/3 Anaplastic undifferentiated carcinoma (C73.9) Y Syn 8691/3 Aortic body paraganglioma (C75.5) Y Reportable for cases


BC Syn Syn

8691/3 Aortic body tumor (C75.5) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

Syn 8691/3 Aorticopulmonary paraganglioma (C75.5) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

Syn 8249/3 Atypical carcinoid tumor Y CC 9687/3 B-ALL [obs] Y Cases diagnosed prior to


RT 8090/3 Basal cell carcinoma with adnexal differentiation (C44. _) N Not reportable

3


Syn 8833/1 Bednar tumor (C44. _) N Cases diagnosed prior to 1/1/2021, report the case and code to 8833/3. Cases diagnosed 1/1/2021 forward are not reportable.

Syn 8151/3 Beta cell adenoma (C25.4) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021.

Syn 8151/3 Beta cell tumor, malignant (C25.4) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021.

NC/T 9819/3 B-lymphocytic leukemia/lymphoma, BCR-ABL1-like Y Reportable for cases diagnosed 1/1/2021 forward

RT 9715/3 Breast implant-associated anaplastic large cell lymphoma (C50. _) Y Reportable for cases diagnosed 1/1/2021 forward

Syn 9699/3 Bronchus associated lymphoid tissue lymphoma Y CC 9687/3 Burkitt cell leukemia (see also M-9687/3) Y Cases diagnosed prior to


CC 9811/3 c-ALL Y Cases diagnosed prior to 1/1/2021 use code 9836/3 Cases diagnosed 1/1/2021 forward use code 9811/3

RT 8140/3 Carcinoma of Skene, Cowper and Littre Glands Y Syn 8589/3 Carcinoma showing thymus-like element Y RT 8020/3 Carcinoma, poorly differentiated, NOS Y BC 8692/3 Carotid body paraganglioma (C75.4) Y Reportable for cases


4


Syn 8692/3 Carotid body tumor (C75.4) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

RT 8693/3 Chemodectoma Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

Syn 8700/3 Chromaffin paraganglioma Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

Syn 8700/3 Chromaffin tumor Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

Syn 8700/3 Chromaffinoma Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

RT 8313/1 Clear cell adenofibroma of borderline malignancy (C56.9) N Not reportable PT 8313/1 Clear cell borderline tumor (C56.9) N Not reportable Syn 8313/1 Clear cell cystic tumor of borderline malignancy (C56.9) N Not reportable Syn 8313/1 Clear cell tumor, atypical proliferation (C56.9) N Not reportable PT 9473/3 CNS Embryonal tumor, NOS Y CC 9811/3 Common ALL Y Cases diagnosed prior to


CC 9811/3 Common precursor B ALL Y Cases diagnosed prior to 1/1/2021 use code 9836/3 Cases diagnosed 1/1/2021 forward use code 9811/3

5


RT 8693/3 Composite paraganglioma Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

RT 8700/3 Composite pheochromocytoma (C74.1) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

RT/BC 8500/2 Cystic hypersecretory carcinoma (C50. _) Y Cases diagnosed prior to 1/1/2021, code to 8508/3. ICD-O-3.2 now lists this term under 8500 with a behavior code of 2.

RT 8020/3 Dedifferentiated carcinoma Y BC 8832/1 Dermatofibrosarcoma protuberans, NOS N Cases diagnosed prior to

1/1/2021, report the case and code to 8832/3. Cases diagnosed 1/1/2021 forward are not reportable.

Syn 8832/1 Dermatofibrosarcoma, NOS N Cases diagnosed prior to 1/1/2021, report the case and code to 8832/3. Cases diagnosed 1/1/2021 forward are not reportable.

Syn 8832/3 Dermatofibrosarcoma, sarcomatous (C44. _) Y RT 9680/3 Diffuse large B-cell lymphoma, activated B-cell subtype Y RT 9680/3 Diffuse large B-cell lymphoma, germinal center B-cell subtype Y PT 9680/3 Diffuse large B-cell lymphoma, NOS Y PT 8408/3 Digital papillary adenocarcinoma (C44. _) Y RT 8720/3 Early/Evolving invasive melanoma (C44. _) Y “Early/evolving invasive

melanoma” is reportable for cases diagnosed 1/1/2021 forward

6


RT 8720/2 Early/Evolving melanoma in situ (C44. _) Y Early/Evolving melanoma in situ is reportable for cases diagnosed 1/1/2021 forward

Syn 8408/3 Eccrine papillary adenocarcinoma (C44. _) Y Syn 8409/3 Eccrine poroma, malignant (C44. _) Y PT 8921/3 Ectomesenchymoma Y Syn 8273/3 Embryoma Y Reportable for cases

diagnosed 1/1/2021 forward RT 8509/3 Endocrine mucin-producing sweat gland carcinoma (C44. _) Y RT 8509/2 Endocrine mucin-producing sweat gland carcinoma in situ (C44. _) Y RT 8158/3 Endocrine tumor, functioning, NOS Y Reportable for cases


RT 8140/3 Endolymphatic sac tumor Y BC 8380/2 Endometrioid intraepithelial neoplasia (C54.1) Y Reportable for cases


NC/T 9749/3 Erdhiem-Chester Disease Y Reportable for cases diagnosed 1/1/2021 forward

PT 9364/3 Ewing sarcoma Y 1/1/2021 forward Ewing sarcoma is the preferred term for 9364/3 and is no longer coded to 9260/3. Cases diagnosed prior to 1/1/2021 should be coded to 9260/3.

BC 8693/3 Extra-adrenal paraganglioma, NOS Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

CC 9687/3 FAB L3 [obs] Y Cases diagnosed prior to 1/1/2021 use code 9826/3

7


Cases diagnosed 1/1/2021 forward use code 9687/3

Syn 8330/3 Follicular adenocarcinoma (C73.9) Y BC 8335/1 Follicular carcinoma, encapsulated N Cases diagnosed prior to

1/1/2021 are reportable and coded to 8335/3. Cases diagnosed 1/1/2021 and after are not reportable.

PT 8330/3 Follicular carcinoma, NOS (C73.9) Y RT 9695/3 Follicular lymphoma, duodenal type (C17.0) Y RT 9690/3 Follicular lymphoma, pediatric type Y PT 8335/1 Follicular tumor of uncertain malignant potential N Syn 8936/3 GANT Y Reportable for cases


RT 8936/3 Gastrointestinal autonomic nerve tumor Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

RT 8936/3 Gastrointestinal pacemaker cell tumor Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

Syn 8936/3 Gastrointestinal stromal sarcoma Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

BC 8936/3 Gastrointestinal stromal tumor Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

Syn 9411/3 Gemistrocytic astrocytoma IDH mutant (C71. _) Y

8


Syn 8936/3 GIST, malignant Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

Syn 8690/3 Glomus jugulare tumor, NOS (C75.5) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

Syn 8315/3 Glycogen-rich clear cell carcinoma Y BC 8620/3 Granulosa cell tumor, adult type (C56.9) Y Granulosa cell tumor, adult

type of the ovary diagnosed prior to 1/1/2021 are not reportable. Cases diagnosed 1/1/2021 forward are now reportable.

Syn 8815/3 Hemangiopericytoma, malignant Y Cases diagnosed prior to 1/1/2021 use code 9150/3 Cases diagnosed 1/1/2021 forward use code 8815/3

PT 9738/3 HHV8-positive diffuse B-cell lymphoma Y PT 8402/3 Hidradenocarcinoma (C44. _) Y Syn 8077/2 High grade squamous intraepithelial lesion Y BC 9725/1 Hydroa vacciniforme-like lymphoproliferative disorder N Cases diagnosed prior to

1/1/2021, report the case and code to 9725/3. Cases diagnosed 1/1/2021 forward are not reportable

BC 9080/1 Immature teratoma of the lung (C34. _) N Immature teratomas arising in lung are not reportable for cases diagnosed 1/1/2021 forward.

BC 9080/1 Immature teratoma of the thymus (C37.9) N Immature teratomas arising in thymus are not reportable for

9


cases diagnosed 1/1/2021 forward.

BC 9080/1 Immature teratoma of the thyroid (C73.9) N Immature teratomas arising in thyroid are not reportable for cases diagnosed 1/1/2021 forward.

Syn 9685/1 In situ follicular lymphoma N In situ lymphoma is not reportable

NC 9695/1 In situ follicular neoplasm N In situ lymphoma is not reportable

Syn 9673/1 In situ mantle cell lymphoma N Not reportable NC/T 9673/1 In situ mantle cell neoplasm N Not reportable Syn 8337/3 Insular carcinoma (C73.9) Y BC 8151/3 Insulinoma, NOS (C25.4) Y Reportable for cases

diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021.

RT 8580/3 Intrapulmonary thymoma (C37.9) Y “Malignant” removed from pre-ICD-O-3.2 term

PT 8589/3 Intrathyroid thymic carcinoma (C73.9) Y RT 8150/3 Islet cell adenocarcinoma (C25.4) Y Reportable for cases


RT 8150/3 Islet cell adenoma (C25.4) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

RT 8150/3 Islet cell adenomatosis (C25.4) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

RT 8150/3 Islet cell carcinoma (C25.4) Y Reportable for cases diagnosed 1/1/2021 forward.

10


Not reportable prior to 1/1/2021

RT 8150/3 Islet cell tumor, NOS (C25.4) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

Syn 8690/3 Jugular paraganglioma (C75.5) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

Syn 8690/3 Jugulotympanic paraganglioma (C75.5) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

RT 8071/3 Keratoacanthoma Y BC 9751/1 Langerhans cell histiocytosis, NOS

Langerhans cell histiocytosis, monostotic Langerhans cell histiocytosis, polystotic

N N N

Please note, these terms are not reportable. Refer to Hematopoietic Database for reportable terms. Cases diagnosed prior to 1/1/2021, report the case and code to 9751/3. Cases diagnosed 1/1/2021 forward are not reportable

Syn 9738/3 Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease

Y

RT 9698/3 Large B-cell lymphoma with IRF4 rearrangement Y RT 8693/3 Laryngeal paraganglioma Y Reportable for cases


PT 8743/3 Low cumulative sun damaged melanoma (C44. _) Y BC 9718/1 Lymphoid papulosis (C44. _) N Cases diagnosed prior to

1/1/2021, report the case and

11


code to 9718/3. Cases diagnosed 1/1/2021 forward are not reportable

BC 9766/3 Lymphomatoid granulomatosis, grade 3 Y Reportable for cases diagnosed 1/1/2021 forward

Syn 9680/3 Malignant lymphoma, large B-cell, diffuse, NOS Y CC 9823/3 Malignant lymphoma, lymphocytic, diffuse, NOS Y Cases diagnosed prior to


CC 9823/3 Malignant lymphoma, lymphocytic, NOS Y Cases diagnosed prior to 1/1/2021 use code 9670/3 Cases diagnosed 1/1/2021 forward use code 9823/3

CC 9823/3 Malignant lymphoma, lymphocytic, well differentiated, diffuse Y Cases diagnosed prior to 1/1/2021 use code 9670/3 Cases diagnosed 1/1/2021 forward use code 9823/3

CC 9823/3 Malignant lymphoma, small B lymphocytic, NOS (see also M-9823/3)

Y Cases diagnosed prior to 1/1/2021 use code 9670/3 Cases diagnosed 1/1/2021 forward use code 9823/3

CC 9823/3 Malignant lymphoma, small cell diffuse Y Cases diagnosed prior to 1/1/2021 use code 9670/3 Cases diagnosed 1/1/2021 forward use code 9823/3

CC 9823/3 Malignant lymphoma, small cell, NOS Y Cases diagnosed prior to 1/1/2021 use code 9670/3 Cases diagnosed 1/1/2021 forward use code 9823/3

CC 9823/3 Malignant lymphoma, small lymphocytic, diffuse Y Cases diagnosed prior to 1/1/2021 use code 9670/3 Cases diagnosed 1/1/2021 forward use code 9823/3

12


CC 9823/3 Malignant lymphoma, small lymphocytic, NOS Y Cases diagnosed prior to 1/1/2021 use code 9670/3 Cases diagnosed 1/1/2021 forward use code 9823/3

PT 8761/3 Malignant melanoma arising in giant congenital nevus (C44. _) Y Syn 8761/3 Malignant melanoma in giant pigmented nevus (C44. _) Y Syn 8982/3 Malignant myoepithelioma Y Syn 8963/3 Malignant rhabdoid tumor Y PT 8770/3 Malignant Spitz tumor (C44. _) Y RT 8510/3 Medullary-like carcinoma Y RT 9477/3 Medulloblastoma, group 3 (C71.6) Y RT 9477/3 Medulloblastoma, group 4 (C71.6) Y RT 9475/3 Medulloblastoma, WNT-activated, anaplastic type (C71.6) Y RT 9475/3 Medulloblastoma, WNT-activated, classic (C71.6) Y RT 9475/3 Medulloblastoma, WNT-activated, large cell type (C71.6) Y Syn 8780/3 Melanoma arising in a blue nevus (C44. _) Y RT 8720/3 Melanoma, meningeal (C70. _) Y RT 8580/3 Metaplastic thymoma (C37.9) Y “Malignant” removed from

pre-ICD-O-3.2 term PT 8407/3 Microcystic adnexal carcinoma (C44. _) Y BC 8690/3 Middle ear paraganglioma (C75.5) Y Reportable for cases


Syn 8244/3 Mixed carcinoid and adenocarcinoma Y RT 8770/3 Mixed epithelioid and spindle cell melanoma Y Syn 8482/3 Mucinous adenocarcinoma, endocervical type Y RT 8470/2 Mucinous cystadenocarcinoma, non-invasive (C25. _) Y BC 8470/2 Mucinous cystic neoplasm with high grade dysplasia (C25. _) Y Syn 9699/3 Mucosa associated lymphoid tissue lymphoma Y Syn 8091/3 Multifocal superficial basal cell carcinoma (C44. _) N Not reportable BC 9505/0 Multinodular and vascolating neuronal tumor (MVNT) (C71.2) Y WHO has not yet assigned a

specific ICD-O code for this

13


neoplasm. In the interest of collecting these tumors, 9505/0 has been assigned by neuropathology experts.

Syn 9732/3 Multiple myeloma (C42.1) Y Syn 9986/3 Myelodysplastic syndrome with 5q deletion (5q-) syndrome Y PT 9986/3 Myelodysplastic syndrome with isolated del (5q) Y PT 9985/3 Myelodysplastic syndrome with multilineage dysplasia Y PT 9993/3 Myelodysplastic syndrome with ring sider0blasts and multilineage

dysplasia Y

PT 9982/3 Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia

Y

PT 9980/3 Myelodysplastic syndrome with single lineage dysplasia Y NC/T 9968/3 Myeloid/lymphoid neoplasm with PCM1-JAK2 Y Reportable for cases

diagnosed 1/1/2021 forward PT 8982/3 Myoepithelial carcinoma Y RT 8150/3 Nesidioblastoma (C25.4) Y Reportable for cases


PT 8249/3 Neuroendocrine tumor, grade 2 Y Y Y

RT 8249/3 Neuroendocrine tumor, grade 3 Y Removed from ICD-O-3.2

9540/1 Neurofibromatosis, NOS N WHO has removed neurofibromatosis from ICD-O-3.2. This disease is not reportable for cases diagnosed 1/1/2018 forward per Solid Tumor Rules

RT 8720/3 Nevoid melanoma (C44. _) Y Syn 8402/3 Nodular hidradenoma, malignant (C44. _) Y

14


RT 8693/3 Nonchromaffin paraganglioma, NOS Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

NC/T 8349/1 Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) C73.9)

N This term was previously coded to 8343/2 and was reportable. This term has changed both ICD-O and behavior codes and is no longer reportable for cases diagnosed 1/1/2021 forward.

NC/T 8349/1 Non-invasive FTP N This term was previously coded to 8343/2 and was reportable. This term has changed both ICD-O and behavior codes and is no longer reportable for cases diagnosed 1/1/2021 forward

Syn 8150/3 Pancreatic endocrine tumor, nonfunctioning (C25.4) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

Syn 8150/3 Pancreatic endocrine tumor, NOS (C25.4) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

BC 8150/3 Pancreatic neuroendocrine tumor, nonfunctioning (C25.4) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021.

PT 8342/3 Papillary carcinoma, oncocytic variant (C73.9) Y Syn 8342/3 Papillary carcinoma, oxyphilic cell (C73.9) Y CC 8470/3 Papillary mucinous cystadenocarcinoma (C56.9) Y Cases diagnosed prior to

1/1/2021 use code 8471/3

15



CC 8470/3 Papillary pseudomucinous cystadenocarcinoma (C56.9) Y Cases diagnosed prior to 1/1/2021 use code 8471/3 Cases diagnosed 1/1/2021 forward use code 8470/3

Syn 8441/3 Papillary serous adenocarcinoma (C56.9) Y Cases diagnosed prior to 1/1/2021 use code 8460/3

Syn 8441/3 Papillary serous cystadenocarcinoma (56.9) Y Cases diagnosed prior to 1/1/2021 use code 8460/3

Syn 8130/1 Papillary transitional cell neoplasm of low-malignant potential (C67. _)

N Not reportable

PT 8130/1 Papillary urothelial neoplasm of low-malignant potential (C67. _) N Not reportable RT 8083/3 Papillary-basaloid carcinoma Y BC 8680/3 Paraganglioma, NOS (C75.5) Y Reportable for cases


BC 8682/3 Parasympathetic paraganglioma (C75.5) Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

RT 8140/3 Parathyroid tumor (C75.0) Y Syn 8700/3 Pheochromoblastoma (C74.1) Y Reportable for cases


BC 8700/3 Pheochromocytoma, NOS (C74.1) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

BC Syn

8833/1 Pigmented dermatofibrosarcoma protuberans (C44. _) N Cases diagnosed prior to 1/1/2021, report the case and code to 8833/3. Cases

16


diagnosed 1/1/2021 forward are not reportable.

PT Syn

8110/3 Pilomatrical carcinoma (C44. _) Pilomatrix carcinoma (C44. _)

N N

Not reportable Not reportable

NC/T 8273/3 Pituitary blastoma (C75.1) Y Reportable for cases diagnosed 1/1/2021 forward

PT 9732/3 Plasma cell myeloma (C42.1) Y Syn 8802/3 Pleomorphic cell sarcoma, undifferentiated Y RT 8802/3 Pleomorphic dermal sarcoma (C44. _) Y Syn 8802/3 Pleomorphic sarcoma Y BC 9971/3 Polymorphic post-transplant lymphoproliferative disorder N Cases diagnosed prior to


Syn 8246/3 Poorly differentiated neuroendocrine neoplasm Y PT 8337/3 Poorly differentiated thyroid carcinoma (C73.9) Y PT 8409/3 Porocarcinoma (C44. _) Y BC 9971/1 Post-transplant lymphoproliferative disorder, NOS N Cases diagnosed prior to


CC 9811/3 Pre-B ALL Y Cases diagnosed prior to 1/1/2021 use code 9836/3 Cases diagnosed 1/1/2021 forward use code 9811/3

CC 9811/3 Precursor B-cell lymphoblastic leukemia (see also M-9728/3) Y Cases diagnosed prior to 1/1/2021 use code 9836/3 Cases diagnosed 1/1/2021 forward use code 9811/3

CC 9811/3 Precursor B-cell lymphoblastic lymphoma (see also M-9836/3) Y Cases diagnosed prior to 1/1/2021 use code 9728/3

17



CC 9837/3 Precursor T-cell lymphoblastic lymphoma (see also M-9837/3) Y Cases diagnosed prior to 1/1/2021 use code 9729/3 Cases diagnosed 1/1/2021 forward use code 9837/3

CC 9811/3 Pre-pre-B ALL Y Cases diagnosed prior to 1/1/2021 use code 9836/3 Cases diagnosed 1/1/2021 forward use code 9811/3

RT 9699/3 Primary choroidal lymphoma (C69.3) Y BC 9718/1 Primary cutaneous CD30+ T cell lymphoproliferative

disorder (C44. _) N Cases diagnosed prior to


BC 9709/1 Primary cutaneous CD4-positive small/medium T-cell lymphoma (C44. _)

N Cases diagnosed prior to 1/1/2021, report the case and code to 9709/3. Cases diagnosed 1/1/2021 forward are not reportable

CC 9811/3 Pro-B ALL Y Cases diagnosed prior to 1/1/2021 use code 9836/3 Cases diagnosed 1/1/2021 forward use code 9811/3

RT 8074/3 Pseudovascular squamous cell carcinoma Y BC 9971/3 PTLD, NOS N Cases diagnosed prior to


Syn 9980/3 Refractory anemia Syn 9982/3 Refractory anemia with excess blasts, NOS Y RT 9985/3 Refractory cytopenia of childhood Y

18


Syn 9985/3 Refractory cytopenia with multilineage dysplasia Y CC 9980/3 Refractory neutropenia Y Cases diagnosed prior to


CC 9980/3 Refractory thrombocytopenia Y Cases diagnosed prior to 1/1/2021 use code 9992/3 Cases diagnosed 1/1/2021 forward use code 9980/3

PT 8963/3 Rhabdoid tumor, NOS Y Syn 8921/3 Rhabdomyosarcoma with ganglionic differentiation Y Syn 8912/3 Rhabdomyosarcoma, spindle-cell/sclerosing type Y Syn 8407/3 Sclerosing sweat duct carcinoma (C44. _) Y RT 8580/3 Sclerosing thymoma (C37.9) Y “Malignant” removed from

pre-ICD-O-3.2 term Syn 8410/3 Sebaceous adenocarcinoma (C44. _) Y PT 8410/3 Sebaceous carcinoma (C44. _) Y PT 9391/3 Sellar ependymoma (C75.1) Y PT 8441/3 Serous cystadenocarcinoma, NOS (56.9) Y Cases diagnosed prior to

1/1/2021 use code 8460/3 Syn 8441/3 Serous papillary adenocarcinoma, NOS (C56.9) Y Cases diagnosed prior to

1/1/2021 use code 8460/3 Syn 8441/3 Serous surface papillary carcinoma (C56.9) Y Cases diagnosed prior to

1/1/2021 use code 8460/3 Syn 8390/3 Skin appendage carcinoma (C44. _) Y Syn 8230/3 Solid adenocarcinoma, NOS Y RT 8452/3 Solid pseudopapillary carcinoma Y PT 8452/3 Solid pseudopapillary neoplasm of the pancreas (C25. _) Y RT 8120/3 Squamotransitional carcinoma Y Syn 8077/2 Squamous dysplasia, high grade Y Syn 8077/2 Squamous intraepithelial neoplasm, grade II See

comments The term “squamous intraepithelial neoplasm,

19


grade II” is NOT reportable for C53. _

PT 8091/3 Superficial basal cell carcinoma (C44. _) N Not reportable RT 8743/3 Superficial spreading melanoma (C44. _) Y RT 8200/3 Thymic carcinoma with adenoid cystic carcinoma-like features

(C37.9) Y

RT 8585/3 Thymoma, atypical (C37.9) Y “Malignant” removed from pre-ICD-O-3.2 term

RT 8585/3 Thymoma, epithelial (C37.9) Y “Malignant” removed from pre-ICD-O-3.2 term

RT 8583/3 Thymoma, lymphocyte-rich (C37.9) Y “Malignant” removed from pre-ICD-O-3.2 term

RT 8583/3 Thymoma, lymphocytic (C37.9) Y “Malignant” removed from pre-ICD-O-3.2 term

RT 8581/3 Thymoma, medullary (C37.9) Y “Malignant” removed from pre-ICD-O-3.2 term

RT 8582/3 Thymoma, mixed type (C37.9) Y “Malignant” removed from pre-ICD-O-3.2 term

PT 8580/3 Thymoma, NOS (C37.9) Y “Malignant” removed from pre-ICD-O-3.2 term

RT 8583/3 Thymoma, organoid (C37.9) Y “Malignant” removed from pre-ICD-O-3.2 term

RT 8583/3 Thymoma, predominantly cortical (C37.9) Y “Malignant” removed from pre-ICD-O-3.2 term

RT 8581/3 Thymoma, spindle cell (C37.9) Y “Malignant” removed from pre-ICD-O-3.2 term

PT 8581/3 Thymoma, type A (C37.9) Y “Malignant” removed from pre-ICD-O-3.2 term

PT 8582/3 Thymoma, type AB (C37.9) Y “Malignant” removed from pre-ICD-O-3.2 term

PT 8583/3 Thymoma, type B1 (C37.9) Y “Malignant” removed from pre-ICD-O-3.2 term

20


PT RT

8584/3 Thymoma, type B2 (C37.9) Thymoma, cortical (C37.9)

Y Y

“Malignant” removed from pre-ICD-O-3.2 term

PT 8585/3 Thymoma, type B3 (C37.9) Y “Malignant” removed from pre-ICD-O-3.2 term

Syn 8131/3 Transitional cell carcinoma, micropapillary Y Syn 8122/3 Transitional cell carcinoma, spindle cell PT 8122/3 Urothelial carcinoma, sarcomatoid Y Syn 8122/3 Urothelial carcinoma, spindle cell Y RT 8693/3 Vagal paraganglioma Y Reportable for cases


RT 9680/3 Vitreoretinal lymphoma (C69. _) Y RT 8054/3 Warty-basaloid carcinoma Y

i ICD-O-3 Implementation Guidelines; 2021 ICD O 3.2 Table 7 Alpha Table; https://www.naaccr.org/icdo3/. Accessed 2/4/2021

21


2021 reportable list - connecticut

Documents